Pfizer announced Friday that a recent large, late-stage trial found that its COVID-19 antiviral pill, Paxlovid, failed at preventing symptomatic infection of people living with a person who has the disease.
The trial enrolled 2,957 participants aged 18 and older who live in the same household as another person who has COVID-19 with symptoms. They were given either Paxlovid or a placebo twice daily for five or 10 days.
Researchers reported that those who took Paxlovid for 5 days were 32 percent less likely to become infected compared to the placebo group. People who took Paxlovid for 10 days were 37 percent less likely to get infected. The results were not statistically significant, however, which means it could possibly be due to chance.
… » Read full article
Bombshell Study – Popular Cooking Staple Linked to Memory Loss?
Aluminum Foil Is a Major Source of Aluminum Exposure, Studies Show Analysis by Dr. Joseph Mercola – November 06, 2024 Admin Note: foil is a staple for many and
